Approval · Notice of Compliance 31437 · 2023
FETZIMA: Notice of Compliance 31437
Issued August 15, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31437
- Date
- August 15, 2023
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FETZIMA | Not yet assigned | — |
Medicinal ingredients
- LEVOMILNACIPRAN 20 MG per CAP
- LEVOMILNACIPRAN 40 MG per CAP
- LEVOMILNACIPRAN 80 MG per CAP
- LEVOMILNACIPRAN 120 MG per CAP